The global postbiotic supplements market is valued at US$ 180.50 Million in 2026 and is forecast to reach US$ 319.51 Million by 2033.
The expanding clinical adoption of gut-brain axis research funded through institutions such as the National Institutes of Health, which is translating into physician-recommended postbiotic protocols drives the market.
Capsules & Tablets hold the largest product type share at 42.0% of the global market in 2026, sustained by practitioner recommendation behaviour in gastroenterology and primary care settings that defaults to standardised dosed formats aligned with pharmaceutical prescription habits.
North America leads the global postbiotic supplements market with a 36.0% share in 2026, driven by the world's largest per-capita functional supplement spending base and a regulatory environment governed by the Dietary Supplement Health and Education Act that provides commercially predictable ingredient approval timelines.
The most actionable opportunity lies in securing formulary and shelf presence within Asia Pacific's institutional healthcare procurement systems, particularly in markets where ageing demographics and government-backed functional food frameworks create government-subsidised demand channels.